
TISSUE REGENIX GROUP PLC - ORD 0.1P
Aktie · GB00B5SGVL29 (XLON)
0,32 GBP
Schlusskurs XLON 06.06.2025:
31,70 GBX
London (XLON) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 14:49
Aktuelle Kurse von TISSUE REGENIX GROUP PLC - ORD 0.1P
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung |
---|---|---|---|---|---|
![]() London |
TRX.L
|
GBX
|
06.06.2025 14:49
|
31,70 GBX
| 31,10 GBX
+1,93 %
|
Performance
Heute | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -0,94 % | -3,94 % | -23,06 % | -44,39 % | -53,72 % | -14,32 % |
Firmenprofil zu TISSUE REGENIX GROUP PLC - ORD 0.1P Aktie
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.
Unternehmensdaten
Name TISSUE REGENIX GROUP PLC - ORD 0.1P
Firma Tissue Regenix Group plc
Website
https://www.tissueregenix.com
Heimatbörse
London

ISIN GB00B5SGVL29
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Daniel Ray Lee
Marktkapitalisierung 26 Mio
Land Großbritannien und Nordirland
Währung GBP
Mitarbeiter 0,1 T
Adresse Unit 3, LS25 2GY Garforth
IPO Datum 2006-12-21
Aktien-Splits
Datum | Split |
---|---|
28.04.2023 | 1:100 |
29.06.2010 | 1:5 |
Ticker Symbole
Name | Symbol |
---|---|
London | TRX.L |
Weitere Aktien
Investoren die TISSUE REGENIX GROUP PLC - ORD 0.1P die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.